Biechele Royce Advisors Bristol Myers Squibb CO Transaction History

Biechele Royce Advisors

$303 Million
Q3 2024

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 08, 2023	SELL	$63.71 - $70.74 $553,385 - $614,447	-8,686 Reduced 7.6%	105,677 $6.76 Million
Q1 2023 May 10, 2023	SELL	$65.71 - $74.53 $335,712 - $380,773	-5,109 Reduced 4.28%	114,363 $7.93 Million
Q4 2022 Feb 13, 2023	SELL	$68.48 - $81.09 $391,157 - $463,186	-5,712 Reduced 4.56%	119,472 $8.6 Million
Q3 2022 Nov 10, 2022	SELL	$0.13 - $76.84 $1,380 - $815,963	-10,619 Reduced 7.82%	125,184 $8.9 Million
Q2 2022 Aug 03, 2022	SELL	$72.62 - $79.98 $421,486 - $464,203	-5,804 Reduced 4.1%	135,803 $10.5 Million
Q1 2022 May 10, 2022	SELL	$61.48 - $73.72 $107,405 - $128,788	-1,747 Reduced 1.22%	141,607 $10.3 Million
Q4 2021 Feb 09, 2022	BUY	$53.63 - $62.52 $306,495 - $357,301	5,715 Added 4.15%	143,354 $8.94 Million
Q3 2021 Nov 12, 2021	BUY	$59.17 - $69.31 $217,390 - $254,644	3,674 Added 2.74%	137,639 $8.14 Million
Q2 2021 Jul 14, 2021	BUY	$61.91 - $67.42 $319,146 - $347,550	5,155 Added 4.0%	133,965 $8.95 Million
Q1 2021 May 12, 2021	BUY	$59.34 - $66.74 $4.43 Million - $4.98 Million	74,600 Added 137.61%	128,810 $8.13 Million
Q4 2020 Feb 04, 2021	SELL	$57.74 - $65.43 $15,647 - $17,731	-271 Reduced 0.5%	54,210 $3.36 Million
Q3 2020 Nov 03, 2020	SELL	$57.43 - $63.64 $91,083 - $100,933	-1,586 Reduced 2.83%	54,481 $3.29 Million
Q2 2020 Jul 30, 2020	SELL	$54.82 - $64.09 $32,563 - $38,069	-594 Reduced 1.05%	56,067 $3.3 Million
Q1 2020 Apr 23, 2020	SELL	$46.4 - $67.43 $145,742 - $211,797	-3,141 Reduced 5.25%	56,661 $3.16 Million
Q4 2019 Jan 31, 2020	SELL	$49.21 - $64.19 $57,329 - $74,781	-1,165 Reduced 1.91%	59,802 $3.84 Million
Q3 2019 Oct 18, 2019	BUY	$42.77 - $50.71 $126,257 - $149,695	2,952 Added 5.09%	60,967 $3.09 Million
Q2 2019 Jul 16, 2019	BUY	$44.62 - $49.34 $138,946 - $153,644	3,114 Added 5.67%	58,015 $2.63 Million
Q1 2019 Apr 17, 2019	BUY	$45.12 - $53.8 $111,762 - $133,262	2,477 Added 4.72%	54,901 $2.62 Million
Q4 2018 Feb 05, 2019	SELL	$48.76 - $63.23 $28,914 - $37,495	-593 Reduced 1.12%	52,424 $2.73 Million
Q3 2018 Oct 30, 2018	SELL	$55.19 - $62.25 $2.51 Million - $2.83 Million	-45,446 Reduced 46.16%	53,017 $3.29 Million
Q2 2018 Jul 20, 2018	BUY	$50.53 - $62.98 $389,283 - $485,197	7,704 Added 8.49%	98,463 $5.45 Million
Q1 2018 Apr 20, 2018	BUY	$59.92 - $68.98 $56,025 - $64,496	935 Added 1.04%	90,759 $5.74 Million
Q4 2017 Feb 08, 2018	BUY	$59.94 - $65.35 $5.38 Million - $5.87 Million	89,824	89,824 $5.5 Million

Others Institutions Holding BMY

# of Institutions

2,536

Shares Held

1.47B

Call Options Held

31.6M

Put Options Held

35M

Vanguard Group Inc Valley Forge, PA

189M
Shares

$10.9 Billion
0.18% of portfolio
Black Rock Inc. New York, NY

159M
Shares

$9.15 Billion
0.15% of portfolio
State Street Corp Boston, MA

92.9M
Shares

$5.36 Billion
0.2% of portfolio
Jpmorgan Chase & CO New York, NY

77.9M
Shares

$4.5 Billion
0.33% of portfolio
Charles Schwab Investment Management Inc San Francisco, CA

61M
Shares

$3.52 Billion
0.61% of portfolio

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $123B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Biechele Royce Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Biechele Royce Advisors with notifications on news.

Account